1 January 2023 - The January 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The January issue of the Schedule includes a number of major new/revised listings:

• Beclomethasone dipropionate with eformoterol fumarate dihydrate and glycopyrronium bromide (Trimbow) - new indication
• Daratumumab with hyaluronidase (Darzalex SC) - new indication
• Doxorubicin hydrochloride (pegylated, liposomal) (Caelyx, Liposomal Doxorubicin Sun) - restriction change
• Eltrombopag olamine (Revolade) - restriction change
• Faricimab (Vabysmo) - new medicine
• Romiplostim (Nplate) - restriction change

Read Summary of PBS changes